Cargando…
中国年轻骨髓增殖性肿瘤患者的临床和基因突变特征
OBJECTIVE: To investigate the clinical and genetic features of young Chinese patients with myeloproliferative neoplasms (MPN). METHODS: In this cross-sectional study, anonymous questionnaires were distributed to patients with MPN patients nationwide. The respondents were divided into 3 groups based...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Editorial office of Chinese Journal of Hematology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10119718/ https://www.ncbi.nlm.nih.gov/pubmed/37356980 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2023.03.004 |
_version_ | 1785029062698205184 |
---|---|
collection | PubMed |
description | OBJECTIVE: To investigate the clinical and genetic features of young Chinese patients with myeloproliferative neoplasms (MPN). METHODS: In this cross-sectional study, anonymous questionnaires were distributed to patients with MPN patients nationwide. The respondents were divided into 3 groups based on their age at diagnosis: young (≤40 years), middle-aged (41–60 years), and elderly (>60 years). We compared the clinical and genetic characteristics of three groups of MPN patients. RESULTS: 1727 assessable questionnaires were collected. There were 453 (26.2%) young respondents with MPNs, including 274 with essential thrombocythemia (ET), 80 with polycythemia vera (PV), and 99 with myelofibrosis. Among the young group, 178 (39.3%) were male, and the median age was 31 (18–40) years. In comparison to middle-aged and elderly respondents, young respondents with MPN were more likely to present with a higher proportion of unmarried status (all P<0.001), a higher education level (all P<0.001), less comorbidity(ies), fewer medications (all P<0.001), and low-risk stratification (all P<0.001). Younger respondents experienced headache (ET, P<0.001; PV, P=0.007; MF, P=0.001) at diagnosis, had splenomegaly at diagnosis (PV, P<0.001), and survey (ET, P=0.052; PV, P=0.063). Younger respondents had fewer thrombotic events at diagnosis (ET, P<0.001; PV, P=0.011) and during the survey (ET, P<0.001; PV, P=0.003). JAK2 mutations were found in fewer young people (ET, P<0.001; PV, P<0.001; MF, P=0.013); however, CALR mutations were found in more young people (ET, P<0.001; MF, P=0.015). Furthermore, mutations in non-driver genes (ET, P=0.042; PV, P=0.043; MF, P=0.004) and high-molecular risk mutations (ET, P=0.024; PV, P=0.023; MF, P=0.001) were found in fewer young respondents. CONCLUSION: Compared with middle-aged and elderly patients, young patients with MPN had unique clinical and genetic characteristics. |
format | Online Article Text |
id | pubmed-10119718 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Editorial office of Chinese Journal of Hematology |
record_format | MEDLINE/PubMed |
spelling | pubmed-101197182023-04-22 中国年轻骨髓增殖性肿瘤患者的临床和基因突变特征 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To investigate the clinical and genetic features of young Chinese patients with myeloproliferative neoplasms (MPN). METHODS: In this cross-sectional study, anonymous questionnaires were distributed to patients with MPN patients nationwide. The respondents were divided into 3 groups based on their age at diagnosis: young (≤40 years), middle-aged (41–60 years), and elderly (>60 years). We compared the clinical and genetic characteristics of three groups of MPN patients. RESULTS: 1727 assessable questionnaires were collected. There were 453 (26.2%) young respondents with MPNs, including 274 with essential thrombocythemia (ET), 80 with polycythemia vera (PV), and 99 with myelofibrosis. Among the young group, 178 (39.3%) were male, and the median age was 31 (18–40) years. In comparison to middle-aged and elderly respondents, young respondents with MPN were more likely to present with a higher proportion of unmarried status (all P<0.001), a higher education level (all P<0.001), less comorbidity(ies), fewer medications (all P<0.001), and low-risk stratification (all P<0.001). Younger respondents experienced headache (ET, P<0.001; PV, P=0.007; MF, P=0.001) at diagnosis, had splenomegaly at diagnosis (PV, P<0.001), and survey (ET, P=0.052; PV, P=0.063). Younger respondents had fewer thrombotic events at diagnosis (ET, P<0.001; PV, P=0.011) and during the survey (ET, P<0.001; PV, P=0.003). JAK2 mutations were found in fewer young people (ET, P<0.001; PV, P<0.001; MF, P=0.013); however, CALR mutations were found in more young people (ET, P<0.001; MF, P=0.015). Furthermore, mutations in non-driver genes (ET, P=0.042; PV, P=0.043; MF, P=0.004) and high-molecular risk mutations (ET, P=0.024; PV, P=0.023; MF, P=0.001) were found in fewer young respondents. CONCLUSION: Compared with middle-aged and elderly patients, young patients with MPN had unique clinical and genetic characteristics. Editorial office of Chinese Journal of Hematology 2023-03 /pmc/articles/PMC10119718/ /pubmed/37356980 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2023.03.004 Text en 2023年版权归中华医学会所有 https://creativecommons.org/licenses/by/3.0/This work is licensed under a Creative Commons Attribution 3.0 License. |
spellingShingle | 论著 中国年轻骨髓增殖性肿瘤患者的临床和基因突变特征 |
title | 中国年轻骨髓增殖性肿瘤患者的临床和基因突变特征 |
title_full | 中国年轻骨髓增殖性肿瘤患者的临床和基因突变特征 |
title_fullStr | 中国年轻骨髓增殖性肿瘤患者的临床和基因突变特征 |
title_full_unstemmed | 中国年轻骨髓增殖性肿瘤患者的临床和基因突变特征 |
title_short | 中国年轻骨髓增殖性肿瘤患者的临床和基因突变特征 |
title_sort | 中国年轻骨髓增殖性肿瘤患者的临床和基因突变特征 |
topic | 论著 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10119718/ https://www.ncbi.nlm.nih.gov/pubmed/37356980 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2023.03.004 |
work_keys_str_mv | AT zhōngguóniánqīnggǔsuǐzēngzhíxìngzhǒngliúhuànzhědelínchuánghéjīyīntūbiàntèzhēng AT zhōngguóniánqīnggǔsuǐzēngzhíxìngzhǒngliúhuànzhědelínchuánghéjīyīntūbiàntèzhēng AT zhōngguóniánqīnggǔsuǐzēngzhíxìngzhǒngliúhuànzhědelínchuánghéjīyīntūbiàntèzhēng AT zhōngguóniánqīnggǔsuǐzēngzhíxìngzhǒngliúhuànzhědelínchuánghéjīyīntūbiàntèzhēng AT zhōngguóniánqīnggǔsuǐzēngzhíxìngzhǒngliúhuànzhědelínchuánghéjīyīntūbiàntèzhēng AT zhōngguóniánqīnggǔsuǐzēngzhíxìngzhǒngliúhuànzhědelínchuánghéjīyīntūbiàntèzhēng AT zhōngguóniánqīnggǔsuǐzēngzhíxìngzhǒngliúhuànzhědelínchuánghéjīyīntūbiàntèzhēng AT zhōngguóniánqīnggǔsuǐzēngzhíxìngzhǒngliúhuànzhědelínchuánghéjīyīntūbiàntèzhēng AT zhōngguóniánqīnggǔsuǐzēngzhíxìngzhǒngliúhuànzhědelínchuánghéjīyīntūbiàntèzhēng AT zhōngguóniánqīnggǔsuǐzēngzhíxìngzhǒngliúhuànzhědelínchuánghéjīyīntūbiàntèzhēng AT zhōngguóniánqīnggǔsuǐzēngzhíxìngzhǒngliúhuànzhědelínchuánghéjīyīntūbiàntèzhēng AT zhōngguóniánqīnggǔsuǐzēngzhíxìngzhǒngliúhuànzhědelínchuánghéjīyīntūbiàntèzhēng AT zhōngguóniánqīnggǔsuǐzēngzhíxìngzhǒngliúhuànzhědelínchuánghéjīyīntūbiàntèzhēng AT zhōngguóniánqīnggǔsuǐzēngzhíxìngzhǒngliúhuànzhědelínchuánghéjīyīntūbiàntèzhēng AT zhōngguóniánqīnggǔsuǐzēngzhíxìngzhǒngliúhuànzhědelínchuánghéjīyīntūbiàntèzhēng AT zhōngguóniánqīnggǔsuǐzēngzhíxìngzhǒngliúhuànzhědelínchuánghéjīyīntūbiàntèzhēng AT zhōngguóniánqīnggǔsuǐzēngzhíxìngzhǒngliúhuànzhědelínchuánghéjīyīntūbiàntèzhēng AT zhōngguóniánqīnggǔsuǐzēngzhíxìngzhǒngliúhuànzhědelínchuánghéjīyīntūbiàntèzhēng AT zhōngguóniánqīnggǔsuǐzēngzhíxìngzhǒngliúhuànzhědelínchuánghéjīyīntūbiàntèzhēng AT zhōngguóniánqīnggǔsuǐzēngzhíxìngzhǒngliúhuànzhědelínchuánghéjīyīntūbiàntèzhēng AT zhōngguóniánqīnggǔsuǐzēngzhíxìngzhǒngliúhuànzhědelínchuánghéjīyīntūbiàntèzhēng AT zhōngguóniánqīnggǔsuǐzēngzhíxìngzhǒngliúhuànzhědelínchuánghéjīyīntūbiàntèzhēng AT zhōngguóniánqīnggǔsuǐzēngzhíxìngzhǒngliúhuànzhědelínchuánghéjīyīntūbiàntèzhēng AT zhōngguóniánqīnggǔsuǐzēngzhíxìngzhǒngliúhuànzhědelínchuánghéjīyīntūbiàntèzhēng AT zhōngguóniánqīnggǔsuǐzēngzhíxìngzhǒngliúhuànzhědelínchuánghéjīyīntūbiàntèzhēng AT zhōngguóniánqīnggǔsuǐzēngzhíxìngzhǒngliúhuànzhědelínchuánghéjīyīntūbiàntèzhēng AT zhōngguóniánqīnggǔsuǐzēngzhíxìngzhǒngliúhuànzhědelínchuánghéjīyīntūbiàntèzhēng AT zhōngguóniánqīnggǔsuǐzēngzhíxìngzhǒngliúhuànzhědelínchuánghéjīyīntūbiàntèzhēng AT zhōngguóniánqīnggǔsuǐzēngzhíxìngzhǒngliúhuànzhědelínchuánghéjīyīntūbiàntèzhēng AT zhōngguóniánqīnggǔsuǐzēngzhíxìngzhǒngliúhuànzhědelínchuánghéjīyīntūbiàntèzhēng AT zhōngguóniánqīnggǔsuǐzēngzhíxìngzhǒngliúhuànzhědelínchuánghéjīyīntūbiàntèzhēng |